Cefdinir
Unchecked
From Pharmacopedia
More actions
Cefdinir
Omnicef (discontinued in US under brand); mostly generic
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Acute otitis media0, Streptococcal pharyngitis0, Acute bacterial sinusitis0, Community-acquired pneumonia (mild outpatient)0, Uncomplicated skin and soft-tissue infections0
Pharmacy
Starting dose
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d
Preparations
300 mg capsules; 125, 250 mg/5 mL suspension
US FDA Max
600 mg/d
Pharmacology
Routes
Oral
Onset
Hours
Duration
12-24 hours
Half-life
~1.7 hours[1]
Bioavailability
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)[1]
Pregnancy
Generally considered safe in pregnancy.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Cefdinir binds penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibits transpeptidation of peptidoglycan cross-links; the result is bactericidal lysis of growing organisms.0 Third-generation cephalosporin spectrum: improved gram-negative coverage relative to first-generation cephalexin while preserving most gram-positive activity. Characteristic harmless red stool with concurrent iron ingestion (cefdinir-iron complex) is occasionally reported and not a sign of GI bleeding[1].
References
edit- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Omnicef (cefdinir), Abbott (originator), current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050739s015,050749s019lbl.pdf